Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863583 | 0.97 | CA14 (0.36) | SSTR4CA14RORCIDO1CPB2 | |
| SCHEMBL7875500 | 0.97 | CA14 (0.35) | SSTR4CA14RORCIDO1CPB2 | |
| SCHEMBL7868697 | 0.83 | CA14 (0.53) | SSTR4CA14RORCCPB2 | |
| SCHEMBL7875570 | 0.83 | SSTR4 (0.36) | SSTR4CA14IDO1EGLN1 | |
| SCHEMBL7871566 | 0.83 | CA14 (0.35) | SSTR4CA14IDO1CPB2 | |
| SCHEMBL7868751 | 0.82 | CA14 (0.35) | SSTR4CA14NPY5R | |
| SCHEMBL7870228 | 0.82 | CA14 (0.44) | SSTR4CA14RORCCPB2 | |
| SCHEMBL7872439 | 0.81 | CA1 (0.35) | RORC | |
| SCHEMBL7872248 | 0.81 | CA14 (0.34) | SSTR4CA14IDO1 | |
| SCHEMBL7868760 | 0.81 | CA14 (0.34) | SSTR4CA14IDO1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | SSTR4 1397/4885CA14 4338/4885RORC 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.